- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05339958
Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hair thinning is a common condition affecting both men and women that is more recently understood to be the result of multiple causes. Although it is generally a benign condition, hair thinning can have a significant, detrimental impact on self-esteem, psychosocial functioning and the overall quality of life of affected individuals. It can also represent a substantial financial burden on individuals seeking treatment.
The objective of this randomized, double-blind, placebo-controlled study is to assess the effectiveness and safety of a novel dietary supplement containing botanical ingredients for hair thinning over the course of six months of continuous daily usage. The study supplement is scientifically formulated to specifically target the multiple underlying causes of hair thinning. In addition to the necessary vitamins, minerals, and proteins to support the nutritional needs of hair, it also contains clinically tested, standardized pharmaceutical-grade botanicals (substances obtained from plants) that target hormones, stress and inflammatory markers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Manhattan Beach, California, United States, 90266
- Ablon Skin Institute and Research Center
-
San Diego, California, United States, 92123
- Therapeutic Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males between 21-55 years of age with self-perceived thinning
- Voluntarily sign and date an informed consent agreement and photo release form approved by the Institutional Review Board
- Clinically confirmed to have hair thinning or loss by the investigator or qualified sub-investigator via physical exam, including only subjects with male pattern hair loss with frontal and/or vertex patterns II, IIA, III, IIIv and IV using the Norwood classification of patterned hair loss in males.
- General good health, as determined by the Investigator or qualified sub-investigator
- Willing and able to attend all study visits and comply with the test product daily instructions.
- Willing to maintain the same hair style and same color for the duration of the study.
- Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
- Willing and able to cooperate with the requirements of the study.
- Able to complete and understand the various rating instruments.
Exclusion Criteria:
- Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
- Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
- Subjects with male pattern hair loss with frontal and/or vertex patterns I, IIIA, IVA, V, VA, VI, VII using the Norwood classification of patterned hair loss in males.
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
- History of surgical correction of hair loss on the scalp (i.e. hair transplant).
- Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
- Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, progesterone, and bicalutamide) within 3 months prior to the Baseline Visit.
- History of burning, flaking, itching, and stinging of the scalp.
- History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
- A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
- A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
- A known allergy to any of the ingredients in the investigational product.
- Utilization of low-level lasers for hair growth in the last three months.
- Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study.
- Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day.
- Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nutraceutical Dietary Supplement Capsule
The nutraceutical capsules are comprised of standardized, natural, medical-grade ingredients.
Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
|
Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health.
These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
|
Placebo Comparator: Placebo Capsule
The placebo capsules contain no active ingredients.
Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
|
The placebo capsules contain no active ingredients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in terminal hair counts
Time Frame: Day 180
|
Changes in terminal hair counts as measured by photorichogram
|
Day 180
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with ≥5% hair growth
Time Frame: Day 180
|
Day 180
|
|
Change in total, terminal and vellus and hair count
Time Frame: Day 180
|
Changes in all hair counts as measured by photorichogram
|
Day 180
|
Change in mean hair width and mean inter-follicular distance
Time Frame: Day 180
|
Changes in hair measurements as measured by photorichogram
|
Day 180
|
Change in terminal to vellus ratio
Time Frame: Day 180
|
Changes in hair ratio as measured by photorichogram
|
Day 180
|
Change in mean number of hairs per follicular unit
Time Frame: Day 180
|
Changes in hair density as measured by photorichogram
|
Day 180
|
Hair Shedding
Time Frame: Day 180
|
Change in Numbers of Hairs Shedded in Hair Pull Test
|
Day 180
|
Subject Assessments
Time Frame: Day 180
|
Subject self assessments of improvement in hair thickness and quality, quality of life, stress, and perception of the study product using questionnaires
|
Day 180
|
Blinded Investigator Assessment
Time Frame: Day 180
|
Changes in Investigator Hair Quality Global Improvement Scale & Investigator Hair Growth Global Improvement Scale assessed by physician using standardized 2-D photographs compared to baseline.
|
Day 180
|
Compiled side effects
Time Frame: Day 180
|
All side effects, including all expected or unexpected side effects, categorized by severity (Mild, moderate, severe) and relatedness to the study product or participation
|
Day 180
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NW-MS-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hair Thinning
-
DeNova ResearchTerminatedHair Loss | Hair ThinningUnited States
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
Arbor Life LabsCompletedAndrogenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning HairUnited States
-
Arbor Life LabsCompletedAndrogenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning HairUnited States
-
NovoBliss Research Pvt LtdZYWIE VENTURES PRIVATE LIMITEDCompletedHair Thinning | Hair Brittle | Dry HairIndia
-
University of MemphisActive, not recruiting
-
VIST - Faculty of Applied SciencesTosla d.o.o.; Slovenian Research and Innovation AgencyEnrolling by invitationHair Loss | Hair ThinningSlovenia
-
University of California, DavisWithdrawnHair Loss | Hair Thinning
-
Ablon Skin Institute Research CenterNutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
Kiierr International, LLCUnknownAndrogenetic Alopecia | Balding | Hair Loss | Thinning HairUnited States
Clinical Trials on Nutrafol® Men Hair Growth Nutraceutical
-
Nutraceutical Wellness Inc.Not yet recruitingHair ThinningUnited States
-
Nutraceutical Wellness Inc.Not yet recruitingHair ThinningUnited States